C4 Therapeutics and Roche Enter New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) April 15, 2026
Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Mocertatug rezetecan achieved confirmed ORR of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent/advanced endometrial cancer in BEHOLD-1 study April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer April 15, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Ph 3 Trial of Novel Telomere-Targeting Anticancer Therapy April 15, 2026
Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer April 15, 2026
Boston Oncology CGT Holding to license Xuanzhu Biopharmaceutical’s Bireociclib and Dirozalkib April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing for Global Development of Solid Tumor CAR-T Therapies April 15, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
Positive Topline Results from Ph 2/3 Registrational Trial (OptimUM-02) of Darovasertib – Crizotinib combo in 1L HLA-A*02:01-neg Metastatic Uveal Melanoma Announced April 15, 2026
Updated Data from Ph 1b/2 Study of Muzastotug + KEYTRUDA in Late-line Patients with MSS CRC Demonstrate Improved Durability of Response April 15, 2026
Comprehensive response to FDA OPDP submitted regarding issues related to a television advertisement and a podcast for ANKTIVA April 15, 2026
Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC Presented April 15, 2026
2-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer presented April 15, 2026
Results from Ph 2 IMGN853-0420 trial show ORR of 62.7% with ELAHERE + chemo followed by ELAHERE monotherapy in patients with ≥50% FRα-expressing PSOC April 15, 2026
